OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Renin-angiotensin System Inhibitors and Development of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
Fereshteh Asgharzadeh, Reza Jafarzadeh Esfehani, Seyed Mahdi Hassanian, et al.
Current Pharmaceutical Design (2020) Vol. 26, Iss. 39, pp. 5079-5085
Closed Access | Times Cited: 17
Fereshteh Asgharzadeh, Reza Jafarzadeh Esfehani, Seyed Mahdi Hassanian, et al.
Current Pharmaceutical Design (2020) Vol. 26, Iss. 39, pp. 5079-5085
Closed Access | Times Cited: 17
Showing 17 citing articles:
Impact of Antihypertensive and Lipid-Lowering Agents on Hepatocellular Carcinoma Risk in Patients with Fatty Liver Disease and Diabetes
Hyo Jung Cho, Eunyoung Lee, Soon Sun Kim, et al.
Digestive Diseases and Sciences (2025)
Closed Access | Times Cited: 1
Hyo Jung Cho, Eunyoung Lee, Soon Sun Kim, et al.
Digestive Diseases and Sciences (2025)
Closed Access | Times Cited: 1
Peroxisome proliferator-activated receptors: Key regulators of tumor progression and growth
Fereshteh Asgharzadeh, Arghavan Memarzia, Vida Alikhani, et al.
Translational Oncology (2024) Vol. 47, pp. 102039-102039
Open Access | Times Cited: 7
Fereshteh Asgharzadeh, Arghavan Memarzia, Vida Alikhani, et al.
Translational Oncology (2024) Vol. 47, pp. 102039-102039
Open Access | Times Cited: 7
The mechanisms of renin–angiotensin system in hepatocellular carcinoma: From the perspective of liver fibrosis, HCC cell proliferation, metastasis and angiogenesis, and corresponding protection measures
Haifeng Zhang, Xiang Gao, Xuan Wang, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 141, pp. 111868-111868
Open Access | Times Cited: 36
Haifeng Zhang, Xiang Gao, Xuan Wang, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 141, pp. 111868-111868
Open Access | Times Cited: 36
The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma
Shigeo Shimose, Atsushi Hiraoka, Andrea Casadei‐Gardini, et al.
Hepatology Research (2022) Vol. 53, Iss. 2, pp. 104-115
Closed Access | Times Cited: 24
Shigeo Shimose, Atsushi Hiraoka, Andrea Casadei‐Gardini, et al.
Hepatology Research (2022) Vol. 53, Iss. 2, pp. 104-115
Closed Access | Times Cited: 24
Angiotensin-converting enzyme 2 and AMPK/mTOR pathway in the treatment of liver fibrosis: Should we consider further implications?
M. Barone
World Journal of Gastroenterology (2024) Vol. 30, Iss. 18, pp. 2391-2396
Open Access | Times Cited: 4
M. Barone
World Journal of Gastroenterology (2024) Vol. 30, Iss. 18, pp. 2391-2396
Open Access | Times Cited: 4
Beyond the Liver: A Comprehensive Review of Strategies to Prevent Hepatocellular Carcinoma
Natchaya Polpichai, Sakditad Saowapa, Pojsakorn Danpanichkul, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 22, pp. 6770-6770
Open Access | Times Cited: 3
Natchaya Polpichai, Sakditad Saowapa, Pojsakorn Danpanichkul, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 22, pp. 6770-6770
Open Access | Times Cited: 3
Renin–angiotensin system inhibitors and risk of hepatocellular carcinoma among patients with hepatitis B virus infection
Ruixuan Chen, Shiyu Zhou, Jiao Liu, et al.
Canadian Medical Association Journal (2024) Vol. 196, Iss. 27, pp. E931-E939
Open Access | Times Cited: 2
Ruixuan Chen, Shiyu Zhou, Jiao Liu, et al.
Canadian Medical Association Journal (2024) Vol. 196, Iss. 27, pp. E931-E939
Open Access | Times Cited: 2
Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation
Émilie Crouchet, Shen Li, Mozhdeh Sojoodi, et al.
JCI Insight (2022) Vol. 7, Iss. 13
Open Access | Times Cited: 10
Émilie Crouchet, Shen Li, Mozhdeh Sojoodi, et al.
JCI Insight (2022) Vol. 7, Iss. 13
Open Access | Times Cited: 10
Hepatocellular Carcinoma Chemoprevention with Generic Agents
Fahmida Rasha, Subhojit Paul, Tracey G. Simon, et al.
Seminars in Liver Disease (2022) Vol. 42, Iss. 04, pp. 501-513
Open Access | Times Cited: 7
Fahmida Rasha, Subhojit Paul, Tracey G. Simon, et al.
Seminars in Liver Disease (2022) Vol. 42, Iss. 04, pp. 501-513
Open Access | Times Cited: 7
Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers as Potential Therapeutic Options for Pancreatic Cancer
Fereshteh Asgharzadeh, Kiarash Roustai Geraylow, Majid Khazaei, et al.
Current Cancer Drug Targets (2022) Vol. 22, Iss. 10, pp. 785-795
Closed Access | Times Cited: 5
Fereshteh Asgharzadeh, Kiarash Roustai Geraylow, Majid Khazaei, et al.
Current Cancer Drug Targets (2022) Vol. 22, Iss. 10, pp. 785-795
Closed Access | Times Cited: 5
The Relationship Between Anti-Hypertensive Drugs and Cancer: Anxiety to be Resolved in Urgent
Rong Yang, Yonggang Zhang, Xiaoyang Liao, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 6
Rong Yang, Yonggang Zhang, Xiaoyang Liao, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 6
New Users of Angiotensin II Receptor Blocker–Versus Angiotensin‐Converting Enzyme Inhibitor–Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD‐BP and SPRINT
Jordan B. King, Ransmond O. Berchie, Catherine G. Derington, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 17
Open Access | Times Cited: 2
Jordan B. King, Ransmond O. Berchie, Catherine G. Derington, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 17
Open Access | Times Cited: 2
Long-Term Prognosis and Related Factors in Patients with Cirrhosis Treated with Balloon-Occluded Retrograde Transvenous Obliteration
Yamato Tamura, Yoshinari Asaoka, Akihito Takeuchi, et al.
Digestive Diseases (2023) Vol. 41, Iss. 5, pp. 789-797
Closed Access | Times Cited: 1
Yamato Tamura, Yoshinari Asaoka, Akihito Takeuchi, et al.
Digestive Diseases (2023) Vol. 41, Iss. 5, pp. 789-797
Closed Access | Times Cited: 1
Impact of Antihypertensive, Lipid-Lowering, and Antiplatelet Agents on Development of Hepatocellular Carcinoma in Patients with Fatty Liver Disease and Diabetes
Hyo Jung Cho, Eunyoung Lee, Soon Sun Kim, et al.
Research Square (Research Square) (2024)
Open Access
Hyo Jung Cho, Eunyoung Lee, Soon Sun Kim, et al.
Research Square (Research Square) (2024)
Open Access
Anticancer Potential of ACEIs/ARBs Administration in Colorectal Cancer
Xin Wang, Haiyun Jing
Current Medicinal Chemistry (2024) Vol. 31, Iss. 30, pp. 4867-4879
Closed Access
Xin Wang, Haiyun Jing
Current Medicinal Chemistry (2024) Vol. 31, Iss. 30, pp. 4867-4879
Closed Access
Evaluating the Effects of Hypotensive Drug Valsartan on Angiogenesis and Associated Breast Ductal Carcinoma Cell Metastasis
Ashok Munjal, Rekha Khandia, Saumi Paladhi, et al.
International Journal of Pharmacology (2022) Vol. 18, Iss. 4, pp. 817-825
Closed Access | Times Cited: 2
Ashok Munjal, Rekha Khandia, Saumi Paladhi, et al.
International Journal of Pharmacology (2022) Vol. 18, Iss. 4, pp. 817-825
Closed Access | Times Cited: 2
The effect of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on progression of gastric cancer: systematic review and meta-analysis
Seyed Ali Mehrdad, Farshad Mirzavi, Seyed Mohammad Seyedi, et al.
Anti-Cancer Drugs (2022)
Closed Access | Times Cited: 1
Seyed Ali Mehrdad, Farshad Mirzavi, Seyed Mohammad Seyedi, et al.
Anti-Cancer Drugs (2022)
Closed Access | Times Cited: 1
